Luisa Carbognin
Overview
Explore the profile of Luisa Carbognin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mastrantoni L, Garufi G, Giordano G, Maliziola N, Di Monte E, Arcuri G, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):11.
PMID: 39910103
Hormone receptor-positive/HER2-negative breast cancer (BC) is the most common subtype of BC and typically occurs as an early, operable disease. In patients receiving neoadjuvant chemotherapy (NACT), pathological complete response (pCR)...
2.
Fabi A, Rossi A, Caputo R, Pisegna S, Scagnoli S, Pantano F, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):22.
PMID: 39843642
Tumor dissemination to the central nervous system (CNS) is almost a rule in the treatment journey of advanced HER2+ breast cancer (BC). Recent results demonstrated high intracranial efficacy with Trastuzumab...
3.
Belluomini L, Avancini A, Sposito M, Pontolillo L, Tregnago D, Trestini I, et al.
Crit Rev Oncol Hematol
. 2024 Jul;
201:104444.
PMID: 39002789
Over the years, advancements in antiemetic drugs have improved chemotherapy-induced nausea and vomiting (CINV) control. However, despite the antiemetics therapies, in a relevant number of adult patients (∼30 %), CINV...
4.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano M, et al.
NPJ Breast Cancer
. 2024 Feb;
10(1):13.
PMID: 38316819
No abstract available.
5.
Pellegrino B, Tommasi C, Serra O, Gori S, Cretella E, Ambroggi M, et al.
J Immunother Cancer
. 2023 Nov;
11(11).
PMID: 38016718
Background: It is possible to induce immunomodulation in HER2-positive breast cancer (BC) by modifying the route of administration of trastuzumab. Methods: In this multicenter randomized phase II trial, all enrolled...
6.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano M, et al.
NPJ Breast Cancer
. 2023 Oct;
9(1):89.
PMID: 37903774
No abstract available.
7.
Sposito M, Belluomini L, Pontolillo L, Tregnago D, Trestini I, Insolda J, et al.
J Pers Med
. 2023 Oct;
13(10).
PMID: 37888038
Targeted therapy (TT) has revolutionized cancer treatment, successfully applied in various settings. Adjuvant TT in resected early-stage gastrointestinal stromal tumors (GIST), melanoma, non-small cell lung cancer (NSCLC), and breast cancer...
8.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano M, et al.
NPJ Breast Cancer
. 2023 Sep;
9(1):73.
PMID: 37684252
The combination of atezolizumab and nab-paclitaxel is recommended in the EU as first-line treatment for PD-L1-positive metastatic triple-negative breast cancer (mTNBC), based on the results of phase III IMpassion130 trial....
9.
Franco A, Di Leone A, Conti M, Fabi A, Carbognin L, Terribile A, et al.
J Pers Med
. 2023 Aug;
13(8).
PMID: 37623530
Introduction: The selection of surgery post-neoadjuvant chemotherapy (NACT) is difficult and based on surgeons' expertise. The aim of this study was to create a post-NEoadjuvant Score System (pNESSy) to choose...
10.
Franco A, Di Leone A, Fabi A, Belli P, Carbognin L, Gambaro E, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37173916
Background: The diffusion of screening programs has resulted in a decrease of cT4 breast cancer diagnosis. The standard care for cT4 was neoadjuvant chemotherapy (NA), surgery, and locoregional or adjuvant...